摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-bromo-4'-bromomethylbiphenyl | 1187523-96-1

中文名称
——
中文别名
——
英文名称
2-bromo-4'-bromomethylbiphenyl
英文别名
4'-bromomethyl-2-bromo-biphenyl;1-Bromo-2-[4-(bromomethyl)phenyl]benzene
2-bromo-4'-bromomethylbiphenyl化学式
CAS
1187523-96-1
化学式
C13H10Br2
mdl
——
分子量
326.03
InChiKey
QUVJSOPZDYJQHV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Catalyzed carbonylation in the synthesis of angiotensin ii antagonists
    申请人:Lek Pharmaceuticals D.D.
    公开号:EP2103609A1
    公开(公告)日:2009-09-23
    One embodiment disclosed in the invention is the efficient synthesis of halogenated biaryl starting material via Grignard chemistry and the use thereof. Another embodiment of the invention is the reaction of catalyzed carbonylation of the 3'-(2'-halo-biphenyl-4-ylmethyl)-1,7'-dimethyl-2'-propyl-1H,3'H-[2,5']bibenzoimidazolyl (TLMH) using either gaseous carbon monoxide in a solvent mixture containing water; or formic acid salts optionally together with acetic acid in anhydrous solvent.
    本发明的一个实施例是通过格氏试剂化学反应高效合成卤代双芳基起始物,并利用其。本发明的另一个实施例是催化羰基化反应3'-(2'-卤代联苯基甲基)-1,7'-二甲基-2'-丙基-1H,3'H-[2,5']双苯并咪唑基(TLMH),使用含水溶剂混合物中的气态一氧化碳或甲酸盐,可选地与乙酸一起在无水溶剂中。
  • 2'-Halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists
    申请人:Lek Pharmaceuticals D.D.
    公开号:EP2103588A1
    公开(公告)日:2009-09-23
    A process for obtaining 2'-halo-4-methylbiphenyls is described, which comprises reacting 4-halotoluene with a 1,2-dihalobenzene in the presence of elemental metal such as magnesium, lithium or zinc, wherein 0 to 0.9 molar, particularly 0 to 0.2 molar excess of 4-halotoluene in regard to 1,2-dihalobenzene is used, and arised organometal intermediates are quenched by elemental halogen. In addition, the coupling of arised 2'-halo-4-methylbiphenyls with 2-(1-propyl)-4-methyl-6-(1'-methylbenzimidazole-2-il)benzimidazole to afford 3'-(2'-halo-biphenyl-4-ylmethyl)-1,7'-dimethyl-2'-propyl-1H,3'H-[2,5']bibenzoimidazolyl, which can be further converted to organometallic compound and said organometallic compound is further reacted with formic acid derivative, such as N,N-dimethylformamide, alkylformiate or carbon dioxide to obtain telmisartan, is also described. Further described is use of in line analytics for monitoring the aforementioned reactions.
    本文描述了一种制备2'-卤代-4-甲基联苯的方法,其中在元素金属(例如镁、锂或锌)存在下,将4-卤代甲苯与1,2-二卤代苯反应,使用0至0.9摩尔,特别是0至0.2摩尔的4-卤代甲苯超量,产生的有机金属中间体通过元素卤素淬灭。此外,将产生的2'-卤代-4-甲基联苯与2-(1-丙基)-4-甲基-6-(1'-甲基苯并咪唑-2-基)苯并咪唑偶联,得到3'-(2'-卤代联苯基-4-基甲基)-1,7'-二甲基-2'-丙基-1H,3'H-[2,5']联苯并咪唑基,可进一步转化为有机金属化合物,该有机金属化合物进一步与甲酸衍生物(如N,N-二甲基甲酰胺、烷基甲酸盐或二氧化碳)反应,制备得到替米沙坦。此外,本文还描述了在线分析用于监测上述反应的使用。
  • CATALYZED CARBONYLATION IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS
    申请人:Casar Zdenko
    公开号:US20110098329A1
    公开(公告)日:2011-04-28
    One embodiment disclosed in the invention is the efficient synthesis of halogenated biaryl starting material via Grignard chemistry and the use thereof. Another embodiment of the invention is the reaction of catalyzed carbonylation of the 3′-(2′-halo-biphenyl-4-ylmethyl)-1,7′-dimethyl-2′-propyl-1H,3′H-[2,5′]bibenzoimidazolyl (TLMH) using either gaseous carbon monoxide in a solvent mixture containing water; or formic acid salts optionally together with acetic acid in anhydrous solvent.
    本发明的一种实施例是通过格氏试剂化学的高效合成卤代双芳基起始物质并利用其。本发明的另一种实施例是催化羰基化反应3'-(2'-卤代联苯基甲基)-1、7'-二甲基-2'-丙基-1H、3'H-[2、5']双苯并咪唑基(TLMH),使用含水溶剂混合物中的气态一氧化碳; 或者在无水溶剂中使用甲酸盐,可选地与乙酸一起。
  • [EN] CATALYZED CARBONYLATION IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS<br/>[FR] CARBONYLATION CATALYSÉE DANS LA SYNTHÈSE D'ANTAGONISTES DE L'ANGIOTENSINE II
    申请人:LEK PHARMACEUTICALS
    公开号:WO2009115585A1
    公开(公告)日:2009-09-24
    One embodiment disclosed in the invention is the efficient synthesis of halogenated biaryl starting material via Grignard chemistry and the use thereof. Another embodiment of the invention is the reaction of catalyzed carbonylation of the 3'-(2'-halo-biphenyl-4-ylmethyl)-1,7'-dimethyl-2'-propyl-1H,3'H-[2,5']bibenzoimidazolyl (TLMH) using either gaseous carbon monoxide in a solvent mixture containing water; or formic acid salts optionally together with acetic acid in anhydrous solvent.
    本发明揭示的一种实施例是通过Grignard化学方法高效合成卤代双芳基起始物,并使用该起始物。本发明的另一种实施例是催化羰基化反应,使用含水溶剂混合物中的气态一氧化碳或甲酸盐(可选地与乙酸一起)在无水溶剂中对3'-(2'-卤代联苯基-4-基甲基)-1,7'-二甲基-2'-丙基-1H,3'H-[2,5']联苯并咪唑基(TLMH)进行反应。
  • 2'-HALOBIPHENYL-4-YL INTERMEDIATES IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS
    申请人:Copar Anton
    公开号:US20110105539A1
    公开(公告)日:2011-05-05
    A process for obtaining 2′-halo-4-methylbiphenyls is described, which comprises reacting 4 halotoluene with a 1,2-dihalobenzene in the presence of elemental metal such as magnesium, lithium or zinc, wherein 0 to 0.9 molar, particularly 0 to 0.2 molar excess of 4-halotoluene in regard to 1,2-dihalobenzene is used, and arised organometal intermediates are quenched by elemental mental halogen. In addition, the coupling of arised 2′-halo-4-methylbiphenyls with 2-(1-propyl)-4-methyl-6-(1′-methylbenzimidazole-2-il)benzimidazole to afford 3′-(2′-halo-biphenyl-4-ylmethyl)-1,7′-dimethyl-2′-propyl-1H,3′H-[2,5′]bibenzoimidazolyl, which can be further converted to organometallic compound and said organometallic compound is further reacted with formic acid derivative, such as N,N-dimethylformamide, alkylformiate or carbon dioxide to obtain telmisartan, is also described. Further described is use of in line analytics for monitoring the aforementioned reactions, process for preparing a pharmaceutical composition and/or dosage for, or use in preparing a medicament.
    本文描述了一种制备2'-卤代-4-甲基联苯的方法,其中使用4-卤代甲苯和1,2-二卤代苯在镁、锂或锌等元素金属存在下反应,其中在1,2-二卤代苯中使用0至0.9摩尔,特别是0至0.2摩尔的4-卤代甲苯过量,并且生成的有机金属中间体通过元素金属卤素淬灭。此外,将生成的2'-卤代-4-甲基联苯与2-(1-丙基)-4-甲基-6-(1'-甲基苯并咪唑-2-基)苯并咪唑偶联,得到3'-(2'-卤代联苯-4-基甲基)-1,7'-二甲基-2'-丙基-1H,3'H-[2,5']双苯并咪唑基,可进一步转化为有机金属化合物,该有机金属化合物与甲酸衍生物(如N,N-二甲基甲酰胺、烷基甲酸酯或二氧化碳)反应,制备得到替米沙坦。此外,本文还描述了在线分析技术用于监测上述反应,以及制备药物组成物和/或剂量的方法,或用于准备药物的用途。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐